FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+86.2%
5Y CAGR+61.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+86.2%/yr
Annual compound
5Y CAGR
+61.7%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
11.1x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$7.41M+64.5%
2024$4.50M+90.2%
2023$2.37M+106.5%
2022$1.15M+120.2%
2021$521000.00-22.1%
2020$669000.00-